I agree that an ethical dilemma will shortly follow. The bar is so low with Remdesivir that any favorable outcomes due to Brilacidin should result in the control group being offered Brilacidin. Imagine watching some patients further degrade and end up knocking on heaven’s door while others get up and walk out. There is just no way to proceed after a while when the effect of the therapeutic becomes so pronounced AND measurable. They will be measuring the viral load and other bio-markers and since we have ZERO therapeutics that have had any real effect it should cause everyone involved to start talking.

Effthecrooksespebozomaxdud!